Healthcare services company Astrana Health reported Q3 CY2025 results beating Wall Street’s revenue expectations, with sales up 99.7% year on year to $956 million. On the other hand, the company’s full-year revenue guidance of $3.14 billion at the midpoint came in 2.2% below analysts’ estimates. Its GAAP profit of $0.23 per share was 46.5% below analysts’ consensus estimates.
Is now the time to buy ASTH? Find out in our full research report (it’s free for active Edge members).
Astrana Health (ASTH) Q3 CY2025 Highlights:
- Revenue: $956 million vs analyst estimates of $950.2 million (99.7% year-on-year growth, 0.6% beat)
- EPS (GAAP): $0.23 vs analyst expectations of $0.43 (46.5% miss)
- Adjusted EBITDA: $68.48 million vs analyst estimates of $67.29 million (7.2% margin, 1.8% beat)
- The company dropped its revenue guidance for the full year to $3.14 billion at the midpoint from $3.2 billion, a 1.9% decrease
- EBITDA guidance for the full year is $205 million at the midpoint, below analyst estimates of $220 million
- Operating Margin: 2%, down from 5.9% in the same quarter last year
- Market Capitalization: $1.67 billion
StockStory’s Take
Astrana Health’s third quarter results were met with a negative market reaction, as the company’s revenue growth was overshadowed by lower-than-expected profitability and a reduction in full-year guidance. Management attributed the robust revenue increase largely to the integration of Prospect Health and continued organic growth, while also acknowledging that operating margins fell due to the mix of new business and ongoing integration costs. CEO Brandon Sim noted, “Medical cost trends across both Prospect and Astrana’s core business remained firmly within expectations,” but the company’s GAAP profit lagged consensus, reflecting integration expenses and a shift in contract timing.
Looking ahead, Astrana Health’s updated guidance is shaped by the delayed transition of several payer contracts from partial to full risk, which are now expected to contribute meaningfully only in 2026. Management remains optimistic that these delays are procedural and not reflective of operational issues, emphasizing that core cost trends and demand from partners remain stable. CEO Brandon Sim stated, “We remain confident that the contribution from these contracts will be realized in 2026 and will further reinforce the strength and durability of our long-term growth trajectory,” while also highlighting potential headwinds in Medicaid and exchange markets due to regulatory developments.
Key Insights from Management’s Remarks
Management pointed to the Prospect Health acquisition, technology investments, and payer contract timing as the main factors shaping the quarter’s performance and revised outlook.
- Prospect Health integration: The acquisition of Prospect Health was a primary growth driver, rapidly expanding Astrana’s scale, provider network, and operational footprint. Management highlighted that integration efforts are progressing, with real-time data visibility and standardization of financial reporting underway. This is expected to yield $12–$15 million in synergies over the next several quarters.
- AI-enabled platform efficiencies: Astrana continued rolling out AI-driven tools for patient risk identification and claims analytics, aiming to reduce administrative overhead and improve care coordination. Management expects these investments to enhance operating leverage and margin expansion in the long run.
- New strategic partnerships: The company expanded its collaboration with Intermountain Health in Nevada, strengthening its position in a high-growth regional market. A new partnership with a Southern California provider group will add over 40,000 shared-risk members in 2026, supporting pipeline strength for the Care Enablement segment.
- Segment performance divergence: The Care Enablement business posted strong margin improvement due to the onboarding of large clients and technology adoption. In contrast, Care Partners’ margins lagged, reflecting higher cost trends in the legacy Prospect business, though management expects gradual convergence with Astrana’s historical performance.
- Contract timing and revenue mix: The downward revision to full-year guidance stemmed from several payer contracts shifting from partial to full risk later than anticipated. Management clarified that this timing issue is procedural, tied to regulatory filings and contract standardization, rather than underlying operational or technology challenges.
Drivers of Future Performance
Astrana’s outlook is driven by delayed full-risk contract transitions, evolving payer partnerships, and regulatory headwinds in Medicaid and exchange markets.
- Delayed full-risk contracts: Management emphasized that several full-risk payer contracts will now take effect in the first quarter of 2026 rather than mid-2025. This shift results from procedural and regulatory factors, not operational setbacks. The company expects these contracts to boost revenue and adjusted EBITDA meaningfully once active.
- Medicaid and exchange pressures: Regulatory uncertainty and elevated disenrollment rates in Medicaid and exchange markets represent ongoing headwinds. While Astrana’s Medicaid trend improved sequentially, CEO Brandon Sim cautioned that “further instability in the regulatory environment” could limit margin expansion in these lines through 2026.
- AI and technology leverage: Continued rollout of AI-enabled care management and claims tools is central to Astrana’s strategy for cost control and operational efficiency. Management expects these investments to drive operating leverage and support margin expansion as new members and contracts are integrated.
Catalysts in Upcoming Quarters
In the coming quarters, the StockStory team will closely watch (1) the pace and effectiveness of full-risk contract activations and integration of new partnerships, (2) stabilization of Medicaid and exchange trends amid regulatory shifts, and (3) realization of expected synergies from the Prospect Health acquisition. The continued rollout of AI-enabled tools and successful onboarding of provider groups will also be important indicators of execution.
Astrana Health currently trades at $32, down from $33.37 just before the earnings. In the wake of this quarter, is it a buy or sell? See for yourself in our full research report (it’s free for active Edge members).
Our Favorite Stocks Right Now
Fresh US-China trade tensions just tanked stocks—but strong bank earnings are fueling a sharp rebound. Don’t miss the bounce.
Don’t let fear keep you from great opportunities and take a look at Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.
StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.